121.50
+2.9(+2.45%)
Currency In EUR
Address
225 Binney Street
Cambridge, MA 02142
United States of America
Phone
617 679 2000
Website
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
7605
First IPO Date
January 03, 2000
| Name | Title | Pay | Year Born |
| Mr. Christopher A. Viehbacher | President, Chief Executive Officer & Director | 5.5M | 1961 |
| Dr. Ginger Gregory Ph.D. | Executive Vice President & Chief Human Resources Officer | 1.42M | 1968 |
| Ms. Nicole Murphy | Executive Vice President and Head of Pharmaceutical Operations & Technology | 1.66M | 1973 |
| Dr. Priya Singhal M.D., M.P.H. | Executive Vice President & Head of Development | 1.74M | 1969 |
| Ms. Susan H. Alexander Esq. | Executive Vice President & Chief Legal Officer | 2.35M | 1957 |
| Mr. Tim Power M.B.A., Ph.D. | Head of Investor Relations | 0 | N/A |
| Ms. Robin C. Kramer | Executive Vice President & Chief Financial Officer | 0 | 1966 |
| Mr. Adam Keeney Ph.D. | Executive Vice President & Head of Corporate Development | 0 | 1977 |
| Ms. Natacha Gassenbach | Chief Communication Officer & Head of Corporate Affairs | 0 | N/A |
| Mr. Sean Godbout | Chief Accounting Officer & Global Corporate Controller | 0 | N/A |
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.